drugset / Trial / NCT05431075

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

NCT05431075 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Timeline

Start
2022-07-01
Primary completion
2024-02-01
Completion
2024-02-01

Outcome

Met primary endpoint

paper As a first-line therapy for H. pylori infection, the eradication rate of the TET-T therapy was noninferior to that of the TET-F therapy PMID 39097924 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tetracycline Unknown 500 mg —
Background Amoxicillin Other / unclassified 1000 mg —
Background Bismuth Potassium Citrate Unknown — —
Background Esomeprazole Small molecule 20 mg —
Background colloidal bismuth pectin Unknown — —